Efficacy News and Research

RSS

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

Cyberonics' FDA-approved VNS Therapy to be featured at the AES meeting

Cyberonics, Inc. announced today that Vagus Nerve Stimulation (VNS) Therapy, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, will be featured in 14 presentations at the American Epilepsy Society's (AES) Annual Meeting, taking place December 4-8 at the Hynes Convention Center in Boston, Massachusetts.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

Study shows herbal medicine is effective for treating acute rhinosinusitis

Rhinosinusitis is an inflammatory process involving one or more of the paranasal sinuses that typically follows a viral upper respiratory tract infection (RTI). The term ‘acute rhinosinusitis’ is used instead of ‘acute sinusitis’ because it is the currently internationally accepted terminology.

4 Dec 2009

FDA clears TSO3's STERIZONE 125L Sterilizer for expanded use

TSO3 Inc., an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that the Company has received clearance from the US Food and Drug Administration to expand the intended use claims for its TSO3 STERIZONE(R) 125L Sterilizer.

4 Dec 2009

Controversy over recent breast cancer screening guidelines discussed

The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Osseon Therapeutics announced today that its Osseoflex (steerable and curvable bone cement delivery needle) and Osseoflex DR (steerable and curvable bone drill) systems for percutaneous vertebral augmentation received Canadian Medical Device Licenses from Health Canada for marketing and clinical use in Canada.

4 Dec 2009

Pfizer announces a $9M cancer research collaboration in British Columbia

Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.

4 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

Usefulness of heart rate variability as a diagnostic for identifying dysfunction established

According to Dr. Daniel Weiss, a recent study of heart rate autonomic markers, and cardiac mortality published in the November issue of Heart Rhythm provides additional support for the usefulness of heart rate variability as a diagnostic for identifying dysfunction (neuropathy in diabetics and others) and cardiovascular mortality, including fatal arrhythmia or sudden cardiac death.

4 Dec 2009

Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial

After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.

3 Dec 2009

Report on the type 2 diabetes drug market in Brazil

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.

3 Dec 2009

Caliper Life Sciences releases Living Image 4.0 software for its IVIS in vivo imaging systems

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 software for IVIS® in vivo imaging systems. Living Image software drives the more than 800 Caliper IVIS systems currently installed in laboratories worldwide.

3 Dec 2009

IsoRay to distribute Oncura's I-125 brachytherapy seed

IsoRay, Inc. announced today that it has signed a distribution agreement with Oncura to distribute the I-125 brachytherapy seed, OncoSeed™.

3 Dec 2009

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).

3 Dec 2009

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

3 Dec 2009

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.

3 Dec 2009

Efficacy News and Research

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Pfizer to present study findings from its expanded breast cancer portfolio

Cyberonics' FDA-approved VNS Therapy to be featured at the AES meeting

FDA approves once-daily SEROQUEL XR Extended Release Tablets

Study shows herbal medicine is effective for treating acute rhinosinusitis

FDA clears TSO3's STERIZONE 125L Sterilizer for expanded use

Controversy over recent breast cancer screening guidelines discussed

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Pfizer announces a $9M cancer research collaboration in British Columbia

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Usefulness of heart rate variability as a diagnostic for identifying dysfunction established

Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial

Report on the type 2 diabetes drug market in Brazil

Caliper Life Sciences releases Living Image 4.0 software for its IVIS in vivo imaging systems

IsoRay to distribute Oncura's I-125 brachytherapy seed

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News